Figure 5 | Scientific Reports

Figure 5

From: Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator

Figure 5

Sulindac decreased tumor vasculature in tumor microenvironment.

(A) CD31 staining revealed that sulindac reduced tumor angiogenesis in 4T1 tumor model. Scale bars, 50 μm. (B) Quantification of tumor vessel densities was assessed. *P < 0.05. (C) The level of VEGF and PlGF was evaluated by RT-PCR. Sulindac reduced pro-angiogenic factors VEGF and PlGF. **P < 0.01.

Back to article page